Faculty Perspectives: PI3K Inhibitors: Efficacy in Hematologic Malignancies and Management of Treatment-Related Adverse Events - TOP
TLG1589
Lymphomas are a heterogeneous group of malignancies
that are associated with substantial morbidity and mortality.
Although standard chemoimmunotherapy regimens
lead to durable remissions in a substantial proportion of
patients, many individuals will relapse and develop refractory
disease. Therefore, a clear need exists for the development of
novel therapies that are designed to treat relapsed/refractory
B-cell malignancies.
The development and utilization of novel therapies, including
small-molecule agents, have undoubtedly altered
the treatment landscape for many indolent
non-Hodgkin B-cell malignancies in the frontline and relapsed/
refractory settings. The availability of such agents as
Bruton tyrosine kinase, BCL2, and phosphoinositide 3-kinase
(PI3K) inhibitors addresses an unmet need among oncologists
and advanced practice providers (APPs) who are seeking additional
therapeutic options for their patients, particularly
those with relapsed/refractory disease.
Results 1 - 2 of 2